½ÃÀ庸°í¼­
»óǰÄÚµå
1494747

¼öÀÇ ÇコÄÉ¾î ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°º°, Áúȯº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®

Veterinary Healthcare Market Forecasts to 2030 - Global Analysis By Product, Disease, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¼öÀÇ ÇコÄÉ¾î ½ÃÀåÀº 2024³â 460¾ï 7,000¸¸ ´Þ·¯ ±Ô¸ðÀ̸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 11.11% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 866¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼öÀÇ ÇコÄɾî´Â µ¿¹°ÀÇ Çູ°ú °Ç°­À» ÁõÁø½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ±¤¹üÀ§ÇÑ ÀÇ·á ¼­ºñ½º¸¦ Æ÷°ýÇÕ´Ï´Ù. ¹Ý·Áµ¿¹°, °¡Ãà, ¾ß»ýµ¿¹°, À̱¹ÀûÀÎ µ¿¹°À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ µ¿¹° Á¾¿¡ ´ëÇÑ ¿¹¹æ, Áø´Ü, Ä¡·á, ÀçȰÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¼öÀÇ»ç´Â ¿Ü°ú, ³»°ú, Ä¡°ú, ¿µ¾çÇÐ, ÇൿÇÐ µîÀÇ Àü¹® Áö½ÄÀ» ÅëÇØ µ¿¹°ÀÇ º¹Áö, °øÁߺ¸°Ç, ȯ°æ º¸È£¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±×µéÀÇ Ã¥ÀÓÀº °³º° µ¿¹°ÀÇ Ä¡·á»Ó¸¸ ¾Æ´Ï¶ó Áúº´ °ü¸®, ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥, ÀÇÇÐ Áö½Ä Çâ»ó°ú °Ç°­ °ü¸® °á°ú °³¼±À» À§ÇÑ ¿¬±¸±îÁö Æ÷ÇÔÇÕ´Ï´Ù.

¹Ì±¹ ¹Ý·Áµ¿¹°¿ëǰÇùȸ(American Pet Products Association)¿¡ µû¸£¸é ¹Ý·Áµ¿¹° ÀÇ·áºñ ÁöÃâÀº ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹Ì±¹ ¼ÒºñÀÚµéÀº 2021³â 1,236¾ï ´Þ·¯¸¦ ¹Ý·Áµ¿¹° ÀÇ·á ¹× Á¦Ç° ÆÇ¸Å¿¡ ÁöÃâÇß½À´Ï´Ù.

¹Ý·Áµ¿¹° º¸ÇèÀÇ Áõ°¡

¹Ý·Áµ¿¹° º¸Çè¿¡ °¡ÀÔÇÏ´Â »ç¶÷µéÀÌ ´Ã¾î³ª¸é¼­ ÀÀ±Þ»óȲÀÌ ¾Æ´Ï´õ¶óµµ µ¿¹°º´¿øÀ» ãÀ¸·Á´Â ÀÇ¿åÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ µ¿¹°ÀÇ ¿¹¹æ ¹× Á¤±âÀûÀÎ Ä¡·á¸¦ ¹Þ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µå´Â °æÁ¦Àû À庮À» ³·Ãä´Ï´Ù. ±× °á°ú, ¼öÀÇ»çµéÀº ´õ ¸¹Àº ȯÀÚ¸¦ À¯Ä¡Çϰí ÷´Ü Àåºñ¿Í ½Ã¼³, ±³À°¿¡ ÅõÀÚÇÒ ¼ö ÀÖ°Ô µÇ¾î Àü¹ÝÀûÀÎ Ä¡·áÀÇ ÁúÀÌ Çâ»óµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¸Çè Àû¿ëÀ» ÅëÇØ º¸È£ÀÚ´Â Ä¡·á °èȹ°ú °æ°ú °üÂû ¾à¼ÓÀ» ÁöŰ°Ô µÇ¾î ¹Ý·Áµ¿¹°ÀÇ °Ç°­ »óŸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æ±â ħü

°æ±â ħü´Â µ¿¹°º´¿ø ÇコÄÉ¾î ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¾î·Á¿î °æÁ¦ »óȲ¿¡¼­´Â ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ µ¿¹°º´¿øÀ» Æ÷ÇÔÇÑ ºñÇʼöÀûÀÎ ÁöÃâÀ» ÁÙÀ̰í, ´õ Àú·ÅÇÑ ´ëü ÀÇ·á ¼­ºñ½º¸¦ ¼±ÅÃÇϰųª Á¤±âÀûÀÎ Áø·á¸¦ ¹Ì·ç´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. ±× °á°ú, µ¿¹° ÀÇ·á ¼­ºñ½º ¹× Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ °¨¼ÒÇϰí, ÀÌ´Â °á±¹ µ¿¹°º´¿ø°ú Á¦¾à»çÀÇ ¼öÀÍ¿¡ ¿µÇâÀ» ¹ÌÄ¡°Ô µË´Ï´Ù. ±×·¯³ª °æ±â ºÒÅõ¸í¼ºÀ¸·Î ÀÎÇØ ¼ÒºñÀÚµéÀÌ ¹Ý·Áµ¿¹° ÀÔ¾çÀ» ¹Ì·ç°Å³ª Æ÷±âÇϸ鼭 ¼ö¿ä°¡ ´õ¿í °¨¼ÒÇÒ °¡´É¼ºµµ ÀÖ½À´Ï´Ù.

µ¿¹° ÀÇ·áÀÇ ¹ßÀü

MRI ¹× CT ½ºÄµ°ú °°Àº ÷´Ü ¿µ»ó ±â¼ú°ú °°Àº Çõ½ÅÀº µ¿¹°ÀÇ º¹ÀâÇÑ º´¸®¸¦ º¸´Ù Á¤È®ÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀǾàǰÀÇ °³¹ß·Î ºÎÀÛ¿ëÀÌ Àû°í ´õ È¿°úÀûÀÎ ¾à¹°À» »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î µ¿¹°ÀÇ Ä¡·á ¼º°ú¿Í »îÀÇ ÁúÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½À ¼ö¼ú ±â¼úÀº ȸº¹ ½Ã°£°ú ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» °¨¼Ò½ÃÄÑ ¼öÀÇÇÐÀº ´õ¿í ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·áÀÇ ÅëÇÕÀ¸·Î ¿ø°ÝÁø·á¿Í ¸ð´ÏÅ͸µÀÌ °¡´ÉÇØÁö¸é¼­ ƯÈ÷ ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀÇ ¼öÀÇÇÐ ¼­ºñ½º Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

¼öÀÇ»ç ºÎÁ·

Áø·á¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â Àü¹®°¡ÀÇ ¼ö°¡ ÁÙ¾îµé¸é ±âÁ¸ ¼öÀÇ»çÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí, ¿¹¾à ´ë±â ½Ã°£ÀÌ ±æ¾îÁö°í, ¼öÀÇÇÐ ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¶³¾îÁö°í, ¼öÀǻ簡 ¹ÙºüÁö¸é¼­ Áø·áÀÇ ÁúÀÌ ¶³¾îÁú ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ¼öÀÇ»ç ºÎÁ·Àº ¶ÇÇÑ ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀ¸·Î ¼öÀÇ»ç Áø·á¼ÒÀÇ È®ÀåÀ» Á¦ÇÑÇÏ°í ¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ °Ç°­ °ü¸®¿¡ ´ëÇÑ Á¢±Ù¼º °ÝÂ÷¸¦ ¾ÇÈ­½Ãų ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸¸¦ ÃßÁøÇϰí Áøº¸¸¦ ±¸ÇöÇÒ ¼öÀÖ´Â Àü¹®°¡°¡ Àû±â ¶§¹®¿¡ÀÌ ºÐ¾ßÀÇ Çõ½ÅÀûÀÎ Ä¡·á ¹× ±â¼ú °³¹ß ¹× µµÀÔÀÌ Á¦Çѵ˴ϴÙ.

COVID-19ÀÇ ¿µÇâ:

COVID-19 »çÅ´ ¹Ý·Áµ¿¹° ÇコÄÉ¾î ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¹Ý·Áµ¿¹° ÁÖÀÎÀÇ Çൿ¿¡ ´«¿¡ ¶ç´Â º¯È­°¡ ³ªÅ¸³ª°í, ¸¹Àº »ç¶÷µéÀÌ Áý¿¡ ¸Ó¹«´Â ½Ã°£ÀÌ ´Ã¾î³ª¸é¼­ ¹Ý·Áµ¿¹°ÀÇ °Ç°­°ú Çູ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹Ý·Áµ¿¹° »çÀ°ÀÇ ±ÞÁõ°ú ¹Ý·Áµ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ °ü½ÉÀº ¿¹¹æ°ü¸®, ¿¹¹æÁ¢Á¾, ¿ø°ÝÀÇ·á »ó´ã µî ¼öÀÇÇÐ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁ³½À´Ï´Ù. ±×·¯³ª ÇÑÆíÀ¸·Î´Â ±ÔÁ¦¿Í ¾ÈÀü Á¶Ä¡·Î ÀÎÇØ ÀϺΠµ¿¹°º´¿øÀÌ ÀϽÃÀûÀ¸·Î ¹®À» ´Ý°í ´ë¸é Áø·á°¡ ÁÙ¾îµé¸é¼­ ÀÏ»óÀûÀÎ Áø·á¿Í ±ä±ÞÇÏÁö ¾ÊÀº Áø·á¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¾Ë·¹¸£±â ºÐ¾ß°¡ °¡Àå Ŭ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¾Ë·¹¸£±â ºÐ¾ß°¡ °¡Àå Å« ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¹Ý·Áµ¿¹° »çÀ°ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾Ë·¹¸£±â¸¦ Æ÷ÇÔÇÑ ¹Ý·Áµ¿¹°ÀÇ °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀ¸·Î ÀÎÇØ ¹Ý·Áµ¿¹° Àü¿ë ¾Ë·¹¸£±â Ä¡·á, Áø´Ü ¹× ÀúÀڱؼº Á¦Ç° ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿¹°º´¿øÀº ¾Ë·¹¸£±â °Ë»ç ¹× Ä¡·á ¿É¼ÇÀ» Æ÷ÇÔÇÑ ¼­ºñ½º¸¦ È®´ëÇϰí ÀÖÀ¸¸ç, Åк¹¼þÀÌ µ¿·á¸¦ À§ÇÑ Á¾ÇÕÀûÀÎ Ä¡·á¸¦ ¿øÇÏ´Â º¸È£ÀÚµéÀ» ²ø¾îµéÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾àȸ»çµéÀº ¹Ý·Áµ¿¹° ¾Ë·¹¸£±â¸¦ °Ü³ÉÇÑ »õ·Î¿î ¾à¹°°ú ¹é½ÅÀ» Ãâ½ÃÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â µ¿¹°º´¿ø ºÎ¹®ÀÔ´Ï´Ù.

µ¿¹°º´¿ø ºÐ¾ß´Â ¹Ý·Áµ¿¹°, °¡Ãà, À̱¹ÀûÀÎ µ¿¹°À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ µ¿¹° Á¾¿¡ ƯȭµÈ ÀǾàǰ, º¸ÃæÁ¦ ¹× ±âŸ °Ç°­ °ü¸® Á¦Ç°À» ±¤¹üÀ§ÇÏ°Ô Á¦°øÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌµé ¾à±¹Àº µ¿¹°¿ë ÀǾàǰÀ» Àü¹®ÀûÀ¸·Î Ãë±ÞÇÔÀ¸·Î½á ±âÁ¸ÀÇ Àΰ£¿ë ¾à±¹¿¡¼­´Â ½±°Ô ±¸ÇÒ ¼ö ¾ø´Â Áß¿äÇÑ ÀǾàǰÀÇ Á¢±Ù¼ºÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¿¹° ¾à±¹Àº Á¾Á¾ µ¿¹° °Ç°­¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» °®Ãá Á÷¿øÀ» °í¿ëÇÏ¿© ¾Ö¿Ïµ¿¹° ¼ÒÀ¯ÀÚ¿Í °¡Ãà »ý»êÀÚ¿¡°Ô °³º°ÀûÀÎ Áöħ°ú Á¶¾ðÀ» Á¦°ø ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÃÖ´ë ½ÃÀå Á¡À¯À²À» °¡Áø Áö¿ª

ºÏ¹Ì´Â µ¿¹°º´¿ø¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ¹Ý·Áµ¿¹°À» À§ÇÑ Ã·´Ü Áø´Ü µµ±¸, Ä¡·á ¿É¼Ç, Àü¹® Áø·á ¼­ºñ½º¸¦ °®Ãá ÃÖ÷´Ü ½Ã¼³À» ¼³¸³Çϰí ÀÖ¾î ¿¹»ó ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µ¿¹°º´¿øÀÇ Áö¿ªÀû È®ÀåÀº µ¿¹°ÀÇ ¾çÁúÀÇ ÀÇ·á¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ¼öÀÇÇÐ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¹æ, Á¶±â ¹ß°ß ¹× °í±Þ Ä¡·á¿¡ ÁßÁ¡À» µÐ ÀÌ º´¿øµéÀº ÀÌ Áö¿ªÀÇ µ¿¹° ÀÇ·á ¼öÁØÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¾Æ½Ã¾ÆÅÂÆò¾çÀº µ¿¹°¿ë ÀǾàǰ ¹× ¼­ºñ½ºÀÇ ¾ÈÀü¼º, À¯È¿¼º ¹× ǰÁúÀ» º¸ÀåÇÔÀ¸·Î½á ¿¹Ãø ±â°£ µ¿¾È ¼öÀͼº ÀÖ´Â ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤ºÎ ±ÔÁ¦¿¡´Â µ¿¹°¿ë ÀǾàǰ ¹× ÇコÄɾî Á¦Ç°ÀÇ µî·Ï, Á¦Á¶, À¯Åë, ÆÇ¸Å¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀÌ Æ÷ÇԵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀ» ½ÃÇàÇÔÀ¸·Î½á Á¤ºÎ´Â ¾÷°è ³» Åõ¸í¼º°ú Ã¥ÀÓ¼ºÀ» ÃËÁøÇϰí Áö¿ª ³» ¼ÒºñÀÚ¿Í ÀÌÇØ°ü°èÀÚÀÇ ½Å·Ú¸¦ ±¸ÃàÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®(ÃÖ´ë 3°³»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤Ä¡, ¿¹Ãø, CAGR(ÁÖ: Ÿ´ç¼º °ËÅä¿¡ µû¸¥)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù¹ý
  • Á¶»ç Á¤º¸ Ãâó
    • 1Â÷ Á¶»ç Á¤º¸ Ãâó
    • 2Â÷ Á¶»ç Á¤º¸ Ãâó
    • °¡Á¤

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ¼öÀÇ ÇコÄÉ¾î ½ÃÀå : Á¦Ç°º°

  • Ä¡·áÁ¦/ÀǾàǰ
  • Áø´Ü Åø
  • ±âŸ Á¦Ç°

Á¦6Àå ¼¼°èÀÇ ¼öÀÇ ÇコÄÉ¾î ½ÃÀå : Áúº´º°

  • ¼ÒÈ­±âÁúȯ
  • ¾Ë·¹¸£±â
  • °üÀý¿°

Á¦7Àå ¼¼°èÀÇ ¼öÀÇ ÇコÄÉ¾î ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼öÀÇ ¾à±¹
  • ¼öÀÇ º´¿ø
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ¼¼°èÀÇ ¼öÀÇ ÇコÄÉ¾î ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦10Àå ±â¾÷ °³¿ä

  • Zoetis Animal Healthcare
  • Ceva Animal Health Inc
  • Elanco Animal Health
  • Phibro Animal Health
  • Boehringer Ingelheim International GmbH
  • SeQuent Scientific Ltd
  • Cargill Inc
  • MSD Animal Health
  • Sanofi-Aventis
  • Bayer Healthcare
  • Novartis International AG
ksm 24.06.21

According to Stratistics MRC, the Global Veterinary Healthcare Market is accounted for $46.07 billion in 2024 and is expected to reach $86.69 billion by 2030 growing at a CAGR of 11.11% during the forecast period. Veterinary healthcare encompasses a broad spectrum of medical services aimed at promoting the well-being and health of animals. It involves preventive measures, diagnostics, treatment, and rehabilitation for various animal species, including pets, livestock, wildlife, and exotic animals. Veterinarians play a crucial role in safeguarding animal welfare, public health, and the environment through their expertise in areas such as surgery, internal medicine, dentistry, nutrition, and behavior. Their responsibilities extend beyond individual animal care to disease control, vaccination programs, and research aimed at advancing medical knowledge and improving healthcare outcomes.

According to the American Pet Products Association, veterinary care spending has been steadily rising, with U.S. consumers spent US$ 123.6 billion in 2021 on veterinarian care and product sales.

Market Dynamics:

Driver:

Rise in pet insurance coverage

With more individuals opting for pet insurance plans, there's an increased willingness to seek veterinary care, even for non-emergency situations. This shift reduces financial barriers that might otherwise deter pet owners from seeking preventive or routine medical attention for their animals. Consequently, veterinarians experience higher patient volumes, enabling them to invest in advanced equipment, facilities, and training, thereby elevating the overall quality of care. Moreover, insurance coverage incentivizes pet owners to adhere to treatment plans and follow-up appointments, leading to better health outcomes for their pets.

Restraint:

Economic downturns

Economic downturns can significantly impact the veterinary healthcare market. During tough economic times, pet owners may cut back on non-essential expenditures, including veterinary care, opting for cheaper alternatives or delaying routine visits. This leads to reduced demand for veterinary services and products, ultimately affecting the revenue streams of veterinary clinics and pharmaceutical companies. However, economic uncertainty may prompt consumers to postpone or forego adopting new pets, further dampening demand.

Opportunity:

Advancements in veterinary medicine

Innovations such as advanced imaging technologies like MRI and CT scans enable more accurate diagnoses of complex conditions in animals. Developments in pharmaceuticals have led to the availability of more effective medications with fewer side effects, improving treatment outcomes and quality of life for animals. Moreover, minimally invasive surgical techniques have reduced recovery times and post-operative complications, further advancing veterinary care. The integration of telemedicine allows for remote consultations and monitoring, increasing accessibility to veterinary services, particularly in underserved areas.

Threat:

Shortage of veterinarians

With fewer professionals available to provide care, there's an increased burden on existing veterinarians, leading to longer wait times for appointments, reduced accessibility to veterinary services, and potentially compromised quality of care due to overwhelmed practitioners. However, this shortage also limits the expansion of veterinary practices into underserved areas, exacerbating disparities in access to healthcare for both companion animals and livestock. It restricts the development and adoption of innovative treatments and technologies within the field, as there are fewer experts available to drive research and implement advancements.

Covid-19 Impact:

The Covid-19 pandemic significantly impacted the veterinary healthcare market as there was a noticeable shift in pet owner behavior, with many people spending more time at home during lockdowns, leading to increased attention to their pets' health and well-being. This surge in pet ownership and concern for pet health translated into higher demand for veterinary services, including preventive care, vaccinations, and telemedicine consultations. However, on the flip side, restrictions and safety measures also led to temporary closures of some veterinary clinics and reduced in-person visits, affecting routine procedures and non-urgent care.

The Allergies segment is expected to be the largest during the forecast period

Allergies segment is expected to be the largest during the forecast period. As pet ownership rises globally, so does awareness of pet health issues, including allergies. This awareness has led to increased investment in research and development of allergy treatments, diagnostics, and hypoallergenic products tailored specifically for pets. Veterinary clinics are expanding their services to include allergy testing and treatment options, attracting pet owners seeking comprehensive care for their furry companions. Moreover, pharmaceutical companies are introducing new medications and vaccines targeting pet allergies, further fueling market growth.

The Veterinary Pharmacies segment is expected to have the highest CAGR during the forecast period

Veterinary Pharmacies segment is expected to have the highest CAGR during the forecast period as these pharmacies offer a wide range of medications, supplements, and other healthcare products specifically formulated for various species, including pets, livestock, and exotic animals. By focusing solely on veterinary medications, these pharmacies ensure the availability of essential drugs that may not be readily accessible in traditional human pharmacies. Moreover, veterinary pharmacies often employ staff with expertise in animal health, enabling them to offer personalized guidance and advice to pet owners and livestock producers.

Region with largest share:

North America region is poised to hold the largest market share throughout the estimated period of time as these increasing investments in veterinary hospitals are leading to the establishment of state-of-the-art facilities equipped with advanced diagnostic tools, treatment options, and specialized care services for pets. The regional expansion of veterinary hospitals is not only improving access to quality healthcare for animals but also driving innovation in veterinary medicine. With a focus on preventive care, early detection, and advanced treatments, these hospitals are raising the standard of veterinary healthcare in the region.

Region with highest CAGR:

Asia Pacific region is estimated to gain profitable growth over the extrapolated period by ensuring the safety, efficacy, and quality of veterinary products and services. Government regulations often include guidelines for the registration, manufacturing, distribution, and marketing of veterinary medicines and healthcare products. By enforcing stringent regulatory standards, governments promote transparency and accountability within the industry, fostering trust among consumers and stakeholders across the region.

Key players in the market

Some of the key players in Veterinary Healthcare market include Zoetis Animal Healthcare, Ceva Animal Health Inc, Elanco Animal Health, Phibro Animal Health, Boehringer Ingelheim International GmbH, SeQuent Scientific Ltd, Cargill Inc, MSD Animal Health, Sanofi-Aventis, Bayer Healthcare and Novartis International AG.

Key Developments:

In September 2022, Merck Animal Health announced the new label indication for both Bravectoand BravectoPlus for topical use in cats to treat and control Asian long-horned tick infestations. Bravectoand BravectoPlus for cats is the first and only U.S. product labeled for treatment and control.

In January 2022, Zoetis announced that the U.S. Food and Drug Administration (FDA) had approved a new label indication for SimparicaTrio (sarolaner, moxidectin, and pyrantel chewable tablets) for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks (black-legged or deer ticks). SimparicaTrio is approved for dogs eight weeks of age and older.

Products Covered:

  • Therapeutics/Drugs
  • Diagnostic Tool
  • Other Products

Diseases Covered:

  • Gastrointestinal Diseases
  • Allergies
  • Arthritis

End Users Covered:

  • Veterinary Pharmacies
  • Veterinary Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Veterinary Healthcare Market, By Product

  • 5.1 Introduction
  • 5.2 Therapeutics/Drugs
  • 5.3 Diagnostic Tool
  • 5.4 Other Products

6 Global Veterinary Healthcare Market, By Disease

  • 6.1 Introduction
  • 6.2 Gastrointestinal Diseases
  • 6.3 Allergies
  • 6.4 Arthritis

7 Global Veterinary Healthcare Market, By End User

  • 7.1 Introduction
  • 7.2 Veterinary Pharmacies
  • 7.3 Veterinary Hospitals
  • 7.4 Other End Users

8 Global Veterinary Healthcare Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Zoetis Animal Healthcare
  • 10.2 Ceva Animal Health Inc
  • 10.3 Elanco Animal Health
  • 10.4 Phibro Animal Health
  • 10.5 Boehringer Ingelheim International GmbH
  • 10.6 SeQuent Scientific Ltd
  • 10.7 Cargill Inc
  • 10.8 MSD Animal Health
  • 10.9 Sanofi-Aventis
  • 10.10 Bayer Healthcare
  • 10.11 Novartis International AG
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦